Relevant bibliographies by topics / Functional gastrointestinal disorders

Academic literature on the topic 'Functional gastrointestinal disorders'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Functional gastrointestinal disorders.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Functional gastrointestinal disorders"

1

Miura, Soichiro, Akira Torii, Seiji Futagami, and Takeshi Mizukami. "Functional Gastrointestinal Disorders." Nihon Naika Gakkai Zasshi 102, no. 1 (2013): 110–30. http://dx.doi.org/10.2169/naika.102.110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Castilloux, Julie, Angela Noble, and Christophe Faure. "FUNCTIONAL GASTROINTESTINAL DISORDERS." Journal of Pediatric Gastroenterology and Nutrition 43, no. 4 (October 2006): E58. http://dx.doi.org/10.1097/00005176-200610000-00170.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Whorwell, P. J. "Functional Gastrointestinal Disorders." Gut 36, no. 2 (February 1, 1995): 320. http://dx.doi.org/10.1136/gut.36.2.320.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hyams, Jeffrey S. "Functional gastrointestinal disorders." Current Opinion in Pediatrics 11, no. 5 (October 1999): 375–78. http://dx.doi.org/10.1097/00008480-199910000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hongo, Michio. "Functional Gastrointestinal Disorders (FGID)." Nihon Naika Gakkai Zasshi 102, no. 1 (2013): 1–3. http://dx.doi.org/10.2169/naika.102.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mearin, Fermín. "Postinfectious Functional Gastrointestinal Disorders." Journal of Clinical Gastroenterology 45 (August 2011): S102—S105. http://dx.doi.org/10.1097/mcg.0b013e31821fbf58.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Banez, Gerard A., and Rita Steffen. "Pediatric Functional Gastrointestinal Disorders." Journal of Developmental & Behavioral Pediatrics 22, no. 6 (December 2001): 444–45. http://dx.doi.org/10.1097/00004703-200112000-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hyman, Paul E., and David R. Fleisher. "Pediatric Functional Gastrointestinal Disorders." Journal of Pediatric Gastroenterology & Nutrition 25 (1997): 11. http://dx.doi.org/10.1097/00005176-199700002-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rasquin-Weber, A., P. E. Hyman, S. Cucchiara, D. R. Fleisher, J. S. Hyams, P. J. Milla, and A. Staiano. "Childhood functional gastrointestinal disorders." Gut 45, Supplement 2 (September 1, 1999): ii60—ii68. http://dx.doi.org/10.1136/gut.45.2008.ii60.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Olden, Kevin W. "The functional gastrointestinal disorders." General Hospital Psychiatry 19, no. 1 (January 1997): 66–67. http://dx.doi.org/10.1016/s0163-8343(96)00109-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Functional gastrointestinal disorders"

1

Fikree, Asma. "Functional gastrointestinal disorders and the joint hypermobility syndrome." Thesis, Queen Mary, University of London, 2013. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8301.

Full text
Abstract:
Despite the fact that functional gastrointestinal disorders (FGID), such as irritable bowel syndrome, are common, our understanding of them is limited. The Joint Hypermobility Syndrome (JHS) is a common non-inflammatory connective tissue disorder which is thought to be associated with FGID although this has never been proven. Thus, further understanding of the link between JHS and GI symptoms is warranted. Our aim was to fully characterise the gastrointestinal (GI) manifestations of JHS, to determine if there is a true association between GI symptoms in JHS and FGID, and to determine the factors that are involved in this association. Using a cross-sectional design I demonstrate in the first study that patients with a known diagnosis of JHS who are referred from rheumatologists to gastroenterologists have significantly increased gastro-oesophageal symptoms, alternating bowel habit, bloating and abdominal pain compared to other patients referred to the GI clinics. Autonomic factors, and to a lesser extent, somatic hypersensitivity factors appear to mediate the association between JHS and gastro-oesophageal symptoms. In the second study, I demonstrate that healthy university students with JHS are more likely to experience postprandial dyspeptic symptoms compared to those without JHS. Although autonomic and somatic symptoms are increased in JHS their presence does not seem to confound the association with GI symptoms in this group of healthy individuals. In a case-control study of patients attending secondary care GI clinics, I demonstrate that JHS is overrepresented in patients with FGID and reflux disease but not in those with organic disease. Furthermore, the association with FGID is specifically with postprandial distress syndrome and this association is dependent on autonomic factors. In the final chapter, I confirm that abnormalities in GI physiology are common in JHS patients with GI symptoms attending a physiology unit. 60% of JHS patients with reflux symptoms have non-erosive pathological acid reflux, 56% with dysphagia have oesophageal hypomotility, and 87% with dyspeptic symptoms have gastroparesis. My studies suggest that there is overlap between JHS, gastro-oeosphageal symptoms, FGID and GI dysmotility. Understanding the mechanisms underlying GI involvement in JHS may further our understanding of FGID.
APA, Harvard, Vancouver, ISO, and other styles
2

Bennett, Ethelle. "Functional gastrointestinal disorders relations between psychosocial factors, symptoms and sensorimotor disturbance /." Connect to full text, 1999. http://hdl.handle.net/2123/410.

Full text
Abstract:
Thesis (Ph. D.)-- University of Sydney, 1999.
Title from title screen (viewed Apr. 21, 2008). Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the Depts. of Psychological Medicine and Medicine. Includes tables. Includes bibliography. Also available in print form.
APA, Harvard, Vancouver, ISO, and other styles
3

Bennett, Ethelle Jeanette. "Functional Gastrointestinal Disorders: relations between psychosocial factors, symptoms and sensorimotor disturbances." University of Sydney. Psychological Medicine, 1999. http://hdl.handle.net/2123/410.

Full text
Abstract:
Although a vast literature attests to the belief that psychosocial disturbance is an important component of functional gastrointestinal disorders (FGID), the relation of life stress, psychological distress and personality to the development of these disorders is poorly understood. The broad objective of this thesis is to provide data on relations between psychosocial factors and FGID, especially irritable bowel syndrome (IBS) and functional dyspepsia (FD), in representative outpatient samples. Issues not previously addressed are examined in a series of studies. The first two studies are concerned with relations between psychosocial factors, extraintestinal (somatic) symptoms and the number and type of FGID syndromes present at consultation and, in IBS patients, the prospective relation of psychosocial factors to changes in symptom intensity over 16 months. The last three studies relate psychosocial factors to gastrointestinal (GI) transit, motor, and sensory function in FGID, abnormalities in these parameters representing the putative origin of symptoms in FGID. In total, 350 patients participated, representing a 95% participation rate. Important features of the methodology include the use of a recently standardised symptom-based classification system for FGID, an objective and reliable interview-based life stress instrument (The Life Events and Difficulties Schedule), and sophisticated and sensitive technologies to assess GI transit, motor and sensory function. Novel measures, which conceptually take into account the chronic, fluctuating and recurrent course of IBS and FD syndromes, and the tendency of these syndromes to coexist, are also included. Thus, measures of symptom outcome assess the number of syndromes present, while the symptom intensity variable reflects the severity and frequency of both FD and IBS symptoms, if both are present. Similarly, with respect to altered transit, and motor and sensory function, physiological outcome variables reflect not only the presence of an abnormality but the number of regions affected, and the type and number of abnormalities present. Cross-sectional findings showed for the first time that psychosocial disturbance is associated with FGID symptomatology in a quantitative manner, that chronic life stress threat is central to this process and this stress-related process is a prominent feature of a particular group of syndromes (ie IBS/FD) defined primarily by the presence of pain and discomfort. A combination of psychological, social and biological factors combined to predict the number of FGID syndromes present at entry into the study. Prominent among them was an angry, reactive and anxious (neurotic) personality, chronic life stress threat, increased coping, poor emotional support and increased age. In addition to a greater number of FD/IBS syndromes, individuals with an anger-reactive response style had experienced more intense pain and discomfort, and displayed more complete sensorimotor disturbance. Longitudinal data demonstrated (also for the first time) the strength, consistency and unequivocal direction of the relation of chronic threat to symptom intensity over time. Almost all of the within subject variance in symptom intensity levels (assessed on 3 occasions over a 16 month period) was explained by the severity of chronic threat during the previous 6 months or more. For 76% of IBS patients, the presence vs the absence of one or more highly threatening chronic stressors predicted with considerable precision, the long-term clinical outcome. Thus, no patient exposed to even one such stressor improved clinically (ie by at least 50%) over the follow-up period, while in contrast, all patients who improved clinically did so in the absence of such a stressor. For 24% of patients, however, failure to improve clinically could not be explained by any psychological, social (including life stress) or demographic factor included in this study. Key risk indicators of a poor outcome at 16 months were identified - chronic life stress threat, the severity of baseline GI symptomatology, and female gender. Life stress is important because it alone determined the magnitude and direction of change in symptom intensity over time, while the severity of baseline GI symptomatology revealed the extent of improvement required to achieve a recovery, and female gender predicted the presence of a larger number of FD/IBS syndromes in women long-term. Widespread hypomotility, which was almost exclusive to women in this study, represents one factor that may inhibit improvement (or rate of improvement) for women over time. Finally, these findings have identified a psychophysiological subgroup, with underlying psychosocial, motor (and perhaps also sensory) dysfunctions that are more specific for women than men, and which does not seem to be distinctive of any particular FGID subgroup.
APA, Harvard, Vancouver, ISO, and other styles
4

Arn, Ingemar. "A bio-psychological analysis of functional gastrointestinal disorders and a clinical trial of its treatment using psychodrama /." Stockholm, 1999. http://diss.kib.ki.se/1999/91-628-3905-5/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yurkiv, O. I. "Features of clinical-paraclinically diagnostics of gastrointestinal functional disorders of group newborns of perinatal risk." Thesis, БДМУ, 2021. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Austin, Philip Daniel. "International Delphi study to assess the need for multiaxial criteria in diagnosis and management of functional gastrointestinal disorders." Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/15842.

Full text
Abstract:
Purpose: While there are diagnostic criteria for functional gastrointestinal disorders (FGIDs), their evaluation is challenging. This is because criteria are based on symptoms, and the underlying pathophysiology is not clear; as such, there are no gold standard tests. Diagnosis is further challenged by considerable clinical overlap between different FGIDs as well as other organic diseases, while many people with FGIDs have more anxiety and depression than healthy individuals. I hypothesised that assessment of separate components of FGIDs that also indicate their effect on the patient could improve diagnosis. My aim was to investigate the evolution of opinions from experts involved in the development of FGID diagnostic criteria on the proposal for the development of multiaxial assessment criteria (MAC) for FGIDs. Methods: I conducted a web-based Delphi study using a group of purposively sampled experts identified from committees of the Rome Foundation and the International Foundation for Gastrointestinal Disorders. From a systematic search of relevant articles, I generated132 items that were sent to experts as a first round survey. The items assessed risk and contributing factors, the therapeutic relationship, areas of evaluation and the advantages and disadvantages of multiaxial assessment. Consensus on an item was reached when 75% of experts indicated that they agreed or strongly agreed with the statement. Key results: 36 of 68 eligible participants (52%) responded to the first round. Consensus was reached on 96 items. Using participant feedback, thematic analysis was used to generate 33 additional items for round two. Thirty-one of 36 participants (86%) replied to rounds two and three. In round two, 19 items gained consensus, and in round three, nine items gained consensus. Participants agreed that multiaxial assessment was needed, using a systematic approach to establish the physiological and psychosocial components of FGIDs. Participants were unable to agree on the importance of physical risk factors such as previous surgery and genetic association. Overall, 124 of the 167 items achieved consensus. Conclusion and inferences: The key finding from my study shows that experts agree that multiaxial assessment of FGIDs is needed. I also identified expert agreement on the consideration of psychological risk factors and the importance of the impact of FGID symptoms on daily life. Findings also show that experts disagreed on the impact of physical risk factors, socioeconomic status and spirituality on people with FGIDs. While experts could not agree on genetic and gender-based risk factors, they considered that these areas are important and require further research.
APA, Harvard, Vancouver, ISO, and other styles
7

Wixner, Jonas. "Gastrointestinal disturbances in hereditary transthyretin amyloidosis." Doctoral thesis, Umeå universitet, Institutionen för folkhälsa och klinisk medicin, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-88745.

Full text
Abstract:
Background Transthyretin amyloid (ATTR) amyloidosis is a systemic disorder caused by amyloid deposits formed by misfolded transthyretin (TTR) monomers. Two main forms exist – wild-type and hereditary ATTR amyloidosis, the latter associated with TTR gene mutations. Wild-type ATTR amyloidosis has a late onset and primarily cardiac manifestations, whereas hereditary ATTR amyloidosis is a rare autosomal dominant condition with a considerable phenotypic diversity. Both disorders are present all over the world, but endemic areas of the hereditary form are found in Sweden, Portugal, Brazil and Japan. Gastrointestinal (GI) complications are common in hereditary ATTR amyloidosis and play an important role in the patients’ morbidity and mortality. Malfunction of the autonomic and enteric nervous systems has been proposed to contribute to the GI disturbances, but the underlying mechanisms have not been fully elucidated. The aims of this thesis were to assess the prevalence of GI disturbances for different subtypes of ATTR amyloidosis, to further explore the mechanisms behind these disturbances, and to evaluate the outcome of the patients’ GI function after liver transplantation, which currently is the standard treatment for hereditary ATTR amyloidosis. Methods The Transthyretin Amyloidosis Outcomes Survey (THAOS) is the first global, multicenter, longitudinal, observational survey that collects data on patients with ATTR amyloidosis. THAOS enrollment data were used to assess the prevalence of GI symptoms and to evaluate their impact on nutritional status (mBMI) and health-related quality of life (EQ-5D Index Score). Data from routine investigations of heart-rate variability and cardio-vascular response to tilt tests were utilized to evaluate the impact of autonomic neuropathy on the scintigraphically measured gastric emptying half-times in Swedish patients with hereditary ATTR amyloidosis. Gastric wall autopsy specimens from Japanese patients with hereditary ATTR amyloidosis and Japanese non-amyloidosis controls were analyzed with immunohistochemistry and computerized image analysis to assess the densities of interstitial cells of Cajal (ICC) and nervous tissue. Data from gastric emptying scintigraphies and validated questionnaires were used to evaluate the outcome of Swedish patients’ GI function after liver transplantation for hereditary ATTR amyloidosis. Results Sixty-three percent of the patients with TTR mutations and 15 % of those with wild-type ATTR amyloidosis reported GI symptoms at enrollment into THAOS. Subsequent analyses focused on patients with TTR mutations and, among them, unintentional weight loss was the most frequent symptom (32 %) followed by early satiety (26 %). Early-onset patients (<50 years of age) reported GI symptoms more frequently than late-onset cases (70 % vs. 50 %, p <0.01), and GI symptoms were more common in patients with the V30M mutation than in those with non-V30M mutations (69 % vs. 56 %, p <0.01). Both upper and lower GI symptoms were significant negative predictors of nutritional status and health-related quality of life (p <0.01 for both). Weak but significant correlations were found between gastric emptying half-times and the function of both the sympathetic (rs = -0.4, p <0.01) and parasympathetic (rs = -0.3, p <0.01) nervous systems. The densities of c-Kit-immunoreactive ICC were significantly lower in the circular (median density 0.0 vs. 2.6, p <0.01) and longitudinal (median density 0.0 vs. 1.8, p <0.01) muscle layers of the gastric wall in patients compared to controls. Yet, no significant differences in protein gene product 9.5-immunoreactive nervous cells were found between patients and controls either in the circular (median density 3.0 vs. 6.8, p = 0.17) or longitudinal (median density 1.4 vs. 2.5, p = 0.10) muscle layers. Lastly, the patients’ GI symptoms scores had increased slightly from before liver transplantation to the follow-ups performed in median two and nine years after transplantation (median score 7 vs. 10 vs. 13, p <0.01). However, their gastric emptying half-times (median half-time 137 vs. 132 vs. 125 min, p = 0.52) and nutritional statuses (median mBMI 975 vs. 991 vs. 973, p = 0.75) were maintained at follow-ups in median two and five years after transplantation. Conclusion GI disturbances are common in hereditary ATTR amyloidosis and have a negative impact on the patients’ nutritional status and health-related quality of life. Fortunately, a liver transplantation appears to halt the progressive GI involvement of the disease, although the patients’ GI symptoms tend to increase after transplantation. An autonomic neuropathy and a depletion of gastrointestinal ICC seem to contribute to the GI disturbances, but additional factors must be involved.
APA, Harvard, Vancouver, ISO, and other styles
8

Huang, Tao. "Toward novel therapeutics for functional constipation: from traditional Chinese medicine herbal formula MaZiRenWan to cyclic spexin analogues." HKBU Institutional Repository, 2017. https://repository.hkbu.edu.hk/etd_oa/388.

Full text
Abstract:
Functional constipation (FC) is a major gastrointestional (GI) disorder which affects about 14% population worldwide. However, due to efficacy and safety concerns, more than 50% FC patients are not completely satisfied with current conventional therapies, thus alternative therapies are needed. A substantial part of FC patients have symptom of slow colonic motility, while therapy targeting a single pathway cannot benefit all of them. In this thesis, we searched for novel FC therapeutics from two distinct sources, both of which can improve colonic motility significantly: (1) MaZiRenWan (MZRW), an herb formula from Traditional Chinese Medicine (TCM); and (2) Spexin (SPX), a newly identified neuropeptide that is deregulated in FC. On the basis of efficacy validation for MZRW by randomized, placebo-controlled clinical studies, we investigated the bioactive compounds and pharmacological actions of MZRW. Firstly, a machine-learning based method, namely MOST, was developed to relate bioactive compounds with their mechanism-of-action targets. MOST demonstrated good performance in 7-fold cross-validation (over 87% accuracy) and temporal validation (over 76% accuracy). In the case laxative effect, MOST predicted that acetylcholinesterase (ACHE) was the mechanism-of-action target of aloe-emodin; in vivo studies validated this prediction. Secondly, we analyzed the bioactive compounds and mechanism-of-actions of MZRW with combination of UPLC-QTOF-MS/MS, clustering analysis, organ bath, and MOST approaches. 97 compounds were identified in MZRW extract, and 35 of them can be found in plasma and feces samples of rats with oral administration of MZRW. Chemical space analysis suggested that these compounds can be classified into component groups, while the corresponding pharmacology can be studied with representative compounds. Emodin, amygdalin, albiflorin, honokiol, and naringin were shown to induce spontaneous contractions of rat colonic smooth muscle in vitro. Biological targets in ACh-, estrogen-, prostaglandin-, cannabinoid-, and purine signaling pathways are able to explain the prokinetic effects of representative compounds and component groups. Pharmacological actions of MZRW are mixture of five classic paradigms. Thirdly, the latest results of three-armed, randomized and controlled clinical study showed that MZRW demonstrated comparable efficacy with the first line drug Senna, the first line drug for constipation in HK, during treatment period, both were better than placebo; and the efficacy was more sustainable in follow-up period when comparing that of Senna and placebo. These data suggested the unique pharmacological profile of MZRW for FC. With pharmacometabolomic analysis, we found that change of oleamide is negatively correlated (pearson r = -0.59, p<0.001) with improvement of Complete Spontaneous Bowel Movement (CSBM) in MZRW group, but not in Senna or placebo group. Oleamide is up-regulated in FC patients compared with healthy controls, and MZRW can significantly reduce oleamide in FC patients (n=30), healthy human volunteers (n=23), and in normal mice (n=12) serum, ileum, and colon. The regulation of oleamide by MZRW is possibly via augmenting FAAH-mediated degradation. Lastly, we investigated the possibility to use SPX, the newly identified, FC-associated neuropeptide to change GI motility. The deregulation of SPX has been found in several disorders including FC, however, the metabolic instability of SPX prevent it to be directly used in clinical practices. Our investigation through combination of molecular dynamics (MD) simulations and NMR analysis suggested a β-turn-helix-β-turn (βαβ) conformation for human spexin (hSPX) adopts in solution. Consistent with this conformation, cyclic analogues of hSPX with a disulfide bond between residue 1 and 13, LH101 (CWTPQAMLYLKGCQ-NH2), activated both GalR2 (EC50=1.19 μM) and GalR3 (EC50=1.56 μM) with potency comparable to wild type, and that the acetylation at the N-terminal, LH101(Ac) raises the potency EC50=0.38 μM on GalR2 and EC50=0.39 μM on GalR3. The serum half lives of LH101 (t1/2=355.7 min) and LH101(Ac) (t1/2=1973.7 min) were significantly longer than the wild type (t1/2=66.5 min), and LH101(Ac) induces the contractions of mice intestinal segment in vitro and attenuates the oleamide-induced slow GI motility in vivo. Collectively, our studies in MZRW suggested that estrogen and oleamide signaling pathways are potential new targets to develop novel therapeutics for FC, while lead compounds targeting these pathways could be found from MZRW. The final study suggested CSAs have potential to be developed as new FC therapy by targeting the galanin receptor associated pathway.
APA, Harvard, Vancouver, ISO, and other styles
9

Lima, Flávia Altaf da Rocha. "Avaliação da eficácia da acupuntura como forma complementar ao tratamento medicamentoso em pacientes com dispepsia funcional." Universidade Federal de Juiz de Fora, 2012. https://repositorio.ufjf.br/jspui/handle/ufjf/1607.

Full text
Abstract:
Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-05-20T12:20:13Z No. of bitstreams: 1 flaviaaltafdarochalima.pdf: 1162345 bytes, checksum: 18a62c489991ceea8aa434e2b2a63f89 (MD5)
Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-07-02T11:21:12Z (GMT) No. of bitstreams: 1 flaviaaltafdarochalima.pdf: 1162345 bytes, checksum: 18a62c489991ceea8aa434e2b2a63f89 (MD5)
Made available in DSpace on 2016-07-02T11:21:12Z (GMT). No. of bitstreams: 1 flaviaaltafdarochalima.pdf: 1162345 bytes, checksum: 18a62c489991ceea8aa434e2b2a63f89 (MD5) Previous issue date: 2012-08-14
FAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Introdução: A dispepsia funcional (DF) representa um transtorno gastrointestinal frequente na prática clínica. Por apresentar mecanismos etiopatogênicos diversos, a terapia medicamentosa não se mostra totalmente eficaz, razão pela qual a busca por terapias complementares como a acupuntura é fundamental. Objetivo: avaliar a eficácia da acupuntura como terapia complementar ao tratamento medicamentoso convencional em pacientes com DF. Método: ensaio clínico randomizado, com portadores de dispepsia funcional, segundo os critérios de Roma III. Dois grupos foram formados: Grupo I (terapia medicamentosa e acupuntura específica) e Grupo II (terapia medicamentosa e acupuntura não específica). Foram avaliados o índice de sintomas gastrointestinais (Gastrointestinal Scale Related Symptoms – GSRS), a presença de transtornos psíquicos (Escala Hospitalar de Ansiedade e Depressão) e a qualidade de vida (Short-form Health Survey – SF 36) no início, no fim e três meses após o tratamento. Resultados: após 4 semanas de tratamento houve melhora dos sintomas gastrointestinais no Grupo I (55 ± 12 vs. 29 ± 8,8; p = 0,001) e Grupo II (50,3 ± 10,2 vs. 46 ± 10,5; p = 0,001). A qualidade de vida foi significativamente melhor no Grupo I (93,4 ± 7,3 vs. 102,4 ± 5,1; p = 0,001). Transtornos de ansiedade (93,3% vs. 0%; p = 0,001) e depressão (46,7% vs. 0%; p = 0,004) foram significativamente menores no Grupo I. Na comparação intergrupos os sintomas gastrointestinais (29 ± 8,8 vs. 46 ± 10,5; p < 0,001) e a qualidade de vida (102,4 ± 5,1 vs. 96 ± 6,1; p = 0,021) foram significativamente melhores no Grupo I. Três meses após o tratamento, os sintomas gastrointestinais permaneceram melhores no Grupo I quando comparados aos valores pré-tratamento (38 ± 11,3 vs. 55 ± 12; p = 0,001). Conclusão: em portadores de dispepsia funcional o tratamento complementar com acupuntura foi superior ao tratamento convencional. A acupuntura pode ser uma terapia complementar eficaz no tratamento de pacientes com DF.
Introduction: Functional dyspepsia (FD) represents a frequent gastrointestinal disorder in clinical practice. By presenting various etiopathogenic mechanisms, often the drug therapy is not entirely effective. Therefore, the search for complementary therapies such as acupuncture is essential. Objective: Evaluate the effectiveness of acupuncture as a complement to conventional treatment in functional dyspepsia patients. Methods: randomized clinical trial with functional dyspepsia patients in according with ROME III criteria. Two groups were created: Group I (drug therapy and specific acupuncture) and Group II (drug therapy and non-specific acupuncture). The gastrointestinal symptoms (Gastrointestinal Scale Related Symptoms – GSRS), presence of psychiatric disorders (Hospital Anxiety and Depression Scale – HADS) and quality of life (Short-form Health Survey – SF 36) were evaluated, at the end and three months after treatment. Results: After 4 weeks of treatment there was significantly improvement of gastrointestinal symptoms in Group I (55 ± 12 vs. 29 ± 8,8; p = 0,001) and Group II (50 ± 10 vs. 46 ± 10,5; p = 0,001). Quality of life was significantly better in Group I (93,4 ± 7,3 vs. 102,4 ± 5,1; p = 0,001). Anxiety and depression disorders were significantly lower in Group I (93% vs. 0%; p = 0,001 and 46% vs. 0%; p = 0,004; respectively). Inter-group, gastrointestinal symptoms comparison and quality of life were significantly better in Group I (29 ± 8,8 vs. 46 ± 10,5; p < 0,001 and 102,4 ± 5,1 vs. 96,4 ± 6,1; p = 0,021; respectively). Three months after the treatment, gastrointestinal symptoms remained best in Group I, when compared to the pre-treatment values (38 ± 11,3 vs. 55 ± 12; p = 0,001). Conclusion: In patients with functional dyspepsia the complementary acupuncture treatment was superior to conventional treatment. Acupuncture as a complementary treatment can be effective in treating patients with FD.
APA, Harvard, Vancouver, ISO, and other styles
10

Huamán, Ríos José Wálter. "Relación entre dieta, función y síntomas digestivos." Doctoral thesis, Universitat Autònoma de Barcelona, 2020. http://hdl.handle.net/10803/670576.

Full text
Abstract:
Els trastorns funcionals digestius són els trastorns més freqüents en gastroenterologia. Es tracta d'un grup de trastorns de la interacció cervell-intestí, que es classifiquen d'acord amb els símptomes predominants, els més coneguts són la dispèpsia funcional, la síndrome d'intestí irritable, el restrenyiment i els trastorns de la defecació. Se sap que hi ha una relació entre la dieta, funció i els símptomes digestius. No obstant això, la fisiopatologia dels trastorns funcionals digestius no està d'el tot aclarida. En aquesta tesi doctoral plantegem la següent hipòtesi general: el contingut intestinal és un factor clau en el desencadenament de símptomes en pacients amb diferents tipus de síndromes digestius funcionals. L'objectiu principal va ser determinar si els factors de determinar el contingut intestinal, tant la dieta com l'hàbit deposicional, influeixen sobre els símptomes digestius funcionals. En primer lloc, vam realitzar un estudi randomitzat, doble cec, en pacients amb trastorns funcionals digestius, on es va comparar l'efecte d'un suplement (2.8 g / dia Bimuno que conté 1.37 g B GOS) més un placebo (dieta mediterrània típica) vs 1 suplement de placebo (2.8 g de xilosa) més una dieta baixa en FODMAPs. L'objectiu d'aquest estudi va ser determinar la influència específica de diferents tipus de residus fermentables de la dieta (prebiòtics i FODMAPs) sobre els símptomes relacionats amb el gas intestinal en pacient amb síndromes funcionals digestius. Els resultats van ser que tots dos tractaments van presentar millora en els scores de símptomes. Tanmateix, les dues estratègies van tenir conseqüències després de discontinuar el tractament. Tot i que la millora dels símptomes persistir 2 setmanes després de l'administració de l'prebiòtic, els símptomes van empitjorar després de discontinuar la dieta baixa en FODMAPs. A més, els tractaments indueixen efectes diferents en la microbiota, en relació a les Bifidobacteris (increment amb prebiòtics i disminució amb la dieta baixa en FODMAP). A continuació, vam realitzar un estudi randomitzat, paral·lel, en pacients amb dispèpsia funcional amb síndrome de distress postprandial i amb restrenyiment funcional amb disinergia defecatòria, on es va comparar la correcció de la disinergia defecatòria mitjançant biofeedback anorectal vs un suplement de fibra (3.5 g de plantago de ovata per dia) durant 4 setmanes. L'objectiu d'aquest estudi va ser determinar el paper fisiopatològic de l'estrenyiment en la dispèpsia funcional, és a dir si el restrenyiment associat influeix sobre els símptomes dispèptics. Els resultats van ser que la correcció de la disinergia defecatòria va estar associat amb una millora en els símptomes dispèptics i aquesta millora subjectiva va estar associada amb una reducció objectiva en el nombre d'evacuacions de gas anal, cap d'aquests efectes es va observar en el grup que va rebre suplements de fibra. Les conclusions d'aquesta tesi doctoral van ser que els factors que determinen el contingut intestinal, tant la dieta com l'hàbit deposicional, influeixen sobre els símptomes digestius funcionals i que els diferents síndromes funcionals digestius comparteixen una base fisiopatològica comú que involucra el contingut intestinal.
Los trastornos funcionales digestivos son los trastornos más frecuentes en gastroenterología. Se trata de un grupo de trastornos de la interacción cerebro-intestino, que se clasifican de acuerdo con los síntomas predominantes, los más conocidos son la dispepsia funcional, el síndrome de intestino irritable, el estreñimiento y los trastornos de la defecación. Se sabe que hay una relación entre la dieta, función y los síntomas digestivos. Sin embargo, la fisiopatología de los trastornos funcionales digestivos no está del todo aclarada. En esta tesis doctoral planteamos la siguiente hipótesis general: el contenido intestinal es un factor clave en el desencadenamiento de síntomas en pacientes con distintos tipos de síndromes digestivos funcionales. El objetivo principal fue determinar si los factores que determinar el contenido intestinal, tanto la dieta como el hábito deposicional, influyen sobre los síntomas digestivos funcionales. En primer lugar, realizamos un estudio randomizado, doble ciego, en pacientes con trastornos funcionales digestivos, donde se comparó el efecto de un suplemento (2.8 g/día Bimuno que contiene 1.37 g B-GOS) más un placebo (dieta mediterránea típica) vs un suplemento de placebo (2.8 g de xilosa) más una dieta baja en FODMAPs. El objetivo de este estudio fue determinar la influencia específica de distintos tipos de residuos fermentables de la dieta (prebióticos y FODMAPs) sobre los síntomas relacionados con el gas intestinal en paciente con síndromes funcionales digestivos. Los resultados fueron que ambos tratamientos presentaron mejoría en los scores de síntomas. Sin embargo, ambas estrategias tuvieron consecuencias después de descontinuar el tratamiento. Aunque la mejoría de los síntomas persistió 2 semanas después de la administración del prebiótico, los síntomas empeoraron después de descontinuar la dieta baja en FODMAPs. Además, los tratamientos inducen efectos diferentes en la microbiota, en relación a las Bifidobacterias (incremento con prebióticos y disminución con la dieta baja en FODMAP). A continuación, realizamos un estudio randomizado, paralelo, en pacientes con dispepsia funcional con síndrome de distress postprandial y con estreñimiento funcional con disinergia defecatoria, donde se comparó la corrección de la disinergia defecatoria mediante biofeedback anorectal vs un suplemento de fibra (3.5 g de plantago de ovata por día) durante 4 semanas. El objetivo de este estudio fue determinar el papel fisiopatológico del estreñimiento en la dispepsia funcional, es decir si el estreñimiento asociado influye sobre los síntomas dispépticos. Los resultados fueron que la corrección de la disinergia defecatoria estuvo asociado con una mejora en los síntomas dispépticos y esta mejoría subjetiva estuvo asociada con una reducción objetiva en el número de evacuaciones de gas anal, ninguno de estos efectos se observó en el grupo que recibió suplementos de fibra. Las conclusiones de esta tesis doctoral fueron que los factores que determinan el contenido intestinal, tanto la dieta como el hábito deposicional, influyen sobre los síntomas digestivos funcionales y que los distintos síndromes funcionales digestivos comparten una base fisiopatológica común que involucra el contenido intestinal.
Functional gastrointestinal disorders are the most common diagnoses in gastroenterology disorders. It is a group of disorders of the gut-brain interaction and are classified according to the predominant symptoms. The best known are functional dyspepsia, irritable bowel syndrome, constipation and defecation disorders. It is known that there is a relationship between diet, function and digestive symptoms. However, the pathophysiology of functional gastrointestinal disorders is not entirely clear. In this doctoral thesis we propose the following general hypothesis: intestinal content is a key factor in triggering symptoms in patients with different types of functional gastrointestinal syndromes. The main aim was to determine if the factors that determine the intestinal content, both the diet and depositional habit, influence functional gastrointestinal symptoms. Firstly, we performed a randomized, parallel and double-blind study of patients with functional gastrointestinal disorders, and compared the effect of a prebiotic supplement (2.8 g/d Bimuno containing 1.37 g B-GOS) plus a placebo (Mediterranean-type diet) versus a placebo supplement (2.8 g xylose) plus a diet low in FODMAP. The arm of this study was to determine the specific influence of different types of fermentable residues from the diet (prebiotics and FODMAP) on gas-related symptoms in patient, with functional gastrointestinal disorders. The results were that both treatments improved the symptoms to a similar extent. However, both strategies had different consequences after treatment discontinuation; while the improvement of symptoms persisted 2 weeks after prebiotic administration was discontinued, the symptoms relapsed after the termination of the low FODMAP diet. Also, both treatments induced different effects on microbiota, particularly in relation to the Bifidobacterium (increased with prebiotic and decreased with low FODMAP diet). Next, we performed a randomized, parallel study of patients with functional dyspepsia with postprandial distress syndrome and functional constipation with dyssynergic defecation and compared correction of dyssynergic defecation by biofeedback techniques vs fiber supplementation (3.5 g plantago ovata per day) for 4 weeks. The arm of this study was to determine the pathophysiologic role of constipation in functional dyspepsia, that is, if the associated constipation influences dyspeptic symptoms. The results were that the correction of dyssynergic defecation was associated with a significant improvement of dyspeptic symptoms and this subjective improvement was associated with an objective reduction in the number of anal gas evacuations. None of these effects were observed in the group that received fiber supplements. The conclusions of this doctoral thesis were that the factors that determine the intestinal content, both the diet and the depositional habit, influence the functional gastrointestinal symptoms and that the different functional gastrointestinal syndromes share a common pathophysiological basis that involves the intestinal content.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Functional gastrointestinal disorders"

1

1948-, Olden Kevin W., ed. Handbook of functional gastrointestinal disorders. New York: M. Dekker, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Drossman, Douglas, Lin Chang, William D. Chey, John Kellow, Jan Tack, and William E. Whitehead, eds. Rome IV Functional Gastrointestinal Disorders. Raleigh, NC USA: The Rome Foundation, 2016. http://dx.doi.org/10.24890/pc.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hongō, Michio, editor of compilation, ed. Functional and GI motility disorders. Basel: Karger, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1939-, Cohen Sidney, and Soloway Roger D, eds. Functional disorders of the gastrointestinal tract. New York: Churchill Livingstone, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fleisher, David R. Management of Functional Gastrointestinal Disorders in Children. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1089-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

A, Drossman Douglas, ed. Understanding the irritable gut: The functional gastrointestinal disorders. McLean, Va: Degnon Associates, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lacy, Brian E., Michael D. Crowell, and John K. DiBaise, eds. Functional and Motility Disorders of the Gastrointestinal Tract. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-1498-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chang, Lin, William D. Chey, John Kellow, Jan Tack, and William E. Whitehead, eds. Rome IV Functional Gastrointestinal Disorders of Gut-Brain Interaction. Raleigh, NC USA: The Rome Foundation, 2016. http://dx.doi.org/10.24890/gb.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mark, Pimentel, Conklin Jeffrey, and SpringerLink (Online service), eds. Color Atlas of High Resolution Manometry. Boston, MA: Springer-Verlag US, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Malfertheiner, P. Functional Gastrointestinal Disorders. S Karger Pub, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Functional gastrointestinal disorders"

1

Banoub, Hany, Hisham M. Nazer, and Sonny K. F. Chong. "Functional Gastrointestinal Disorders." In Textbook of Clinical Pediatrics, 1829–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02202-9_185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lal, Pooja, and Michael F. Vaezi. "Functional Heartburn." In Gastrointestinal Motility Disorders, 135–42. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59352-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wald, Arnold. "Functional Anorectal Pain/Tenesmus." In Gastrointestinal Motility Disorders, 391–96. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59352-4_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Levine, Marc S. "Gastric Functional Tests: Upper Gatrointestinal Barium Studies." In Gastrointestinal Motility Disorders, 317–29. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59352-4_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Guadagnoli, Livia A., John E. Pandolfino, and Rena Yadlapati. "Functional Swallowing Disorders." In Gastrointestinal and Liver Disorders in Women’s Health, 19–34. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-25626-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hojsak, Iva. "Probiotics in Functional Gastrointestinal Disorders." In Advances in Experimental Medicine and Biology, 121–37. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/5584_2018_321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Quigley, Eamonn M. M. "Functional Gastrointestinal Disorders in Adults." In World Review of Nutrition and Dietetics, 87–94. Basel: S. KARGER AG, 2013. http://dx.doi.org/10.1159/000347200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Indrio, Flavia, and Giuseppe Riezzo. "Functional Gastrointestinal Disorders in Children." In World Review of Nutrition and Dietetics, 79–86. Basel: S. KARGER AG, 2013. http://dx.doi.org/10.1159/000345737.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vlieger, A. M., and Marc A. Benninga. "Hypnotherapy in Functional Gastrointestinal Disorders." In Pediatric Neurogastroenterology, 593–98. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-15229-0_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Fleisher, David R. "Functional Disorders of Elimination." In Management of Functional Gastrointestinal Disorders in Children, 25–86. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1089-2_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Functional gastrointestinal disorders"

1

Lee, Q. J., W. P. Park, D. Lim, D. G. Woo, C. Y. Ko, D. H. Lee, Y. H. Lee, H. S. Kim, H. R. Yoon, and T. M. Shin. "Ultrasonic System for Diagnosis of Functional Gastrointestinal Disorders: Development, Verification and Clinical Trials." In ASME 2007 2nd Frontiers in Biomedical Devices Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/biomed2007-38030.

Full text
Abstract:
The number of people who are suffering from Functional gastrointestinal disorders is increasing. There are, however, rare diagnostic methods for the functional gastrointestinal disorders because functional disorders show no evidence of organic and physical causes [1, 2]. Recently our research group identified that the gastrointestinal tract well in the patients with the functional gastrointestinal disorders is more rigid than healthy people. we noticed it with palpating the abdominal regions overlaying the gastrointestinal tract. Therefore we developed a system to detect the rigid organs with ultrasonic technique, which can quantify the characteristic above related to the rigidity of the gastrointestinal tract well.
APA, Harvard, Vancouver, ISO, and other styles
2

Bhuvaneswari, P. T. V., S. Nilamani, S. Praveen Kumar, and G. Prudvi Rajeswar. "Design of Diagnostic System for Functional Gastrointestinal Disorders." In 2012 4th International Conference on Computational Intelligence and Communication Networks (CICN). IEEE, 2012. http://dx.doi.org/10.1109/cicn.2012.92.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Realpozo, Pamela Munguía, Claudia Mendoza Pinto, Mario García Carrasco, Socorro Méndez Martínez, Tania Mogollan Delfín, Aurelio López Colombo, and Aurelio López Colombo. "THU0272 FUNCTIONAL GASTROINTESTINAL DISORDERS IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.2642.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mehran, Y. Zandi, A. M. Nasrabadi, and M. R. Hashemi Golpayegani. "An Investigation on Chaotic Approach to Detect Functional Gastrointestinal Disorders." In 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2007. http://dx.doi.org/10.1109/iembs.2007.4352711.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Staunton, Aimee, Amelia Kataria Golestaneh, Stephen Allen, and Manjula Velayudhan Nair. "P16 Diagnosis and management of functional gastrointestinal disorders: a clinical audit." In Abstracts of the BSPGHAN Virtual Annual Meeting, 27–29 April 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/flgastro-2021-bspghan.26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Inayet, Nashiz, Jamal Hayat, Arvind Kaul, and Andrew Poullis. "PWE-137 Functional gastrointestinal disorders(FGID) in systemic lupus erythematosus (SLE) patients." In British Society of Gastroenterology, Annual General Meeting, 4–7 June 2018, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-bsgabstracts.431.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Albusoda, Ahmed, Kathrine Friss, Max Gysan, James Ruffle, Qasim Aziz, and Adam Farmer. "OWE-026 Conditioned pain modulation in functional gastrointestinal disorders: systematic review & meta-analysis." In British Society of Gastroenterology, Annual General Meeting, 4–7 June 2018, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-bsgabstracts.414.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Milošić, Katarina, Mirna Natalija Aničić, Lana Omerza, Irena Senečić-Čala, Jurica Vuković, and Duška Tješić-Drinković. "251 Functional gastrointestinal disorders in a tertiary outpatient setting – a three-year period outcome." In 10th Europaediatrics Congress, Zagreb, Croatia, 7–9 October 2021. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2021. http://dx.doi.org/10.1136/archdischild-2021-europaediatrics.251.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Parker, Sophie, Olafur Palsson, David Sanders, Magnus Simren, Ami Sperber, Hans Tornblom, William Whitehead, Heidi Urwin, and Imran Aziz. "OTH-5 Functional gastrointestinal disorders and associated health impairment in individuals with coeliac disease." In Abstracts of the BSG Annual Meeting, 8–12 November 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2021-bsg.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Inayet, Nashiz, Jamal Hayat, Maite Tome, Arvind Kaul, Ann Child, and Andrew Poullis. "PWE-136 functional gastrointestinal disorders (FGID) in ehlers danlos type III (hypermobile) and marfan syndrome patients." In British Society of Gastroenterology, Annual General Meeting, 4–7 June 2018, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-bsgabstracts.430.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Functional gastrointestinal disorders"

1

Wang, Huashuai, Ning Ding, Yanbo Tang, and Yongheng He. Tianshu (ST25) for functional gastrointestinal disorders: a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dai, Ning, Qingyun He, Qiao Wen, Yifei Zhang, Shibing Liang, Jiali Wei, Jingli Xing, and Jianping Liu. Placebo effect in patients with diarrhea-type irritable bowel syndrome: a literature review of randomized, placebo-controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0019.

Full text
Abstract:
Review question / Objective: The aim of this systematic review is to explore the magnitude of the placebo effect in randomized controlled trials for diarrhea-type irritable bowel syndrome and to understand possible relevant factors that affect the placebo effect. Condition being studied: Irritable bowel syndrome is a chronic functional gastrointestinal disorder characterized by abdominal pain related to defecation and a change in frequency and form of stool. Epidemiological study indicates that the prevalence of irritable bowel syndrome in different countries is high. It is estimated conservatively that direct costs related to irritable bowel syndrome causes a huge economic burden in the United States. In the latest Rome IV criteria, irritable bowel syndrome is divided into 4 subtypes based on abnormal bowel habits: irritable bowel syndrome with predominant constipation, irritable bowel syndrome with predominant diarrhea, irritable bowel syndrome with mixed bowel habits, and irritable bowel syndrome unclassified. Regarding treatment for irritable bowel syndrome, there is no cure or curative treatment. Any agent should be compared with placebo to identify its efficacy. In fact, the placebo response rate of irritable bowel syndrome is high. However, the placebo response rate of IBS-D and the moderators of the magnitude of the placebo response rate are not clear.
APA, Harvard, Vancouver, ISO, and other styles
3

Dai, Ning, Qingyun He, Qiao Wen, Yifei Zhang, Shibing Liang, Jiali Wei, Jingli Xing, and Jianping Liu. Placebo effect in patients with diarrhea-type irritable bowel syndrome: a literature review of randomized, placebo-controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0019.

Full text
Abstract:
Review question / Objective: The aim of this systematic review is to explore the magnitude of the placebo effect in randomized controlled trials for diarrhea-type irritable bowel syndrome and to understand possible relevant factors that affect the placebo effect. Condition being studied: Irritable bowel syndrome is a chronic functional gastrointestinal disorder characterized by abdominal pain related to defecation and a change in frequency and form of stool. Epidemiological study indicates that the prevalence of irritable bowel syndrome in different countries is high. It is estimated conservatively that direct costs related to irritable bowel syndrome causes a huge economic burden in the United States. In the latest Rome IV criteria, irritable bowel syndrome is divided into 4 subtypes based on abnormal bowel habits: irritable bowel syndrome with predominant constipation, irritable bowel syndrome with predominant diarrhea, irritable bowel syndrome with mixed bowel habits, and irritable bowel syndrome unclassified. Regarding treatment for irritable bowel syndrome, there is no cure or curative treatment. Any agent should be compared with placebo to identify its efficacy. In fact, the placebo response rate of irritable bowel syndrome is high. However, the placebo response rate of IBS-D and the moderators of the magnitude of the placebo response rate are not clear.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Functional gastrointestinal disorders' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography